Format

Send to

Choose Destination
Sex Med Rev. 2018 Jul;6(3):358-366. doi: 10.1016/j.sxmr.2018.01.003. Epub 2018 Mar 22.

Effect Size in Efficacy Trials of Women With Decreased Sexual Desire.

Author information

1
Pykonsult LLC, New Fairfield, CT, USA. Electronic address: robertepyke@gmail.com.
2
Departments of Psychiatry and Neurobehavioral Sciences, and Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA.

Abstract

BACKGROUND:

Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size small for medications vs placebo, but substantial for cognitive behavior therapy (CBT) or mindfulness meditation training (MMT) vs wait list. However, we lack comparisons of the effect sizes for the active intervention itself, for the control treatment, and for the differential between the two.

AIM:

For efficacy trials of HSDD in women, compare effect sizes for medications (testosterone/testosterone transdermal system, flibanserin, and bremelanotide) and placebo vs effect sizes for psychotherapy and wait-list control.

METHODS:

We conducted a literature search for mean changes and SD on main measures of sexual desire and associated distress in trials of medications, CBT, or MMT. Effect size was used as it measures the magnitude of the intervention without confounding by sample size.

OUTCOMES:

Cohen d was used to determine effect sizes.

RESULTS:

For medications, mean (SD) effect size was 1.0 (0.34); for CBT and MMT, 1.0 (0.36); for placebo, 0.55 (0.16); and for wait list, 0.05 (0.26).

CLINICAL TRANSLATION:

Recommendations of psychotherapy over medication for treatment of HSDD are premature and not supported by data on effect sizes. Active participation in treatment conveys considerable non-specific benefits. Caregivers should attend to biological and psychosocial elements, and patient preference, to optimize response.

CONCLUSIONS:

Few clinical trials of psychotherapies were substantial in size or utilized adequate control paradigms. Medications and psychotherapies had similar, large effect sizes. Effect size of placebo was moderate. Effect size of wait-list control was very small, about one quarter that of placebo. Thus, a substantial non-specific therapeutic effect is associated with receiving placebo plus active care and evaluation. The difference in effect size between placebo and wait-list controls distorts the value of the subtraction of effect of the control paradigms to estimate intervention effectiveness. Pyke RE, Clayton AH. Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sex Med Rev 2018;6:358-366.

KEYWORDS:

Bremelanotide; Cognitive Behavior Therapy; Effect Size; Flibanserin; Hypoactive Sexual Desire Disorder; Mindfulness

PMID:
29576442
DOI:
10.1016/j.sxmr.2018.01.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center